DFTX
Definium Therapeutics Inc
NASDAQ · Pharmaceuticals
$16.90
+0.65 (+4.00%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 685.27M | 628.04M | 535.94M |
| Net Income | 136.42M | 119.21M | 84.03M |
| EPS | — | — | — |
| Profit Margin | 19.9% | 19.0% | 15.7% |
| Rev Growth | -7.8% | +7.1% | -9.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 422.39M | 382.18M | 352.68M |
| Total Equity | 596.50M | 672.97M | 673.84M |
| D/E Ratio | 0.71 | 0.57 | 0.52 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 222.00M | 198.31M | 161.40M |
| Free Cash Flow | 100.39M | 95.21M | 82.42M |